Video
Dr. Atkins Discusses the IMmotion150 Trial in RCC
Author(s):
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma.
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma (RCC).
VEGF inhibitors are a predominant treatment approach in RCC, but there are data that suggest that VEGF may inhibit the immune system in the tumor microenvironment. Atkins says that this sparked interest in exploring combinations with checkpoint inhibitors in this disease.
The IMmotion150 trial randomized patients to either atezolizumab (Tecentriq) alone, atezolizumab plus bevacizumab (Avastin), or sunitinib (Sutent).
